Potential acquisition
July 9, 2010
MARKET analysts at
Datamonitor have tipped the target
of a rumoured upcoming $20
billion acquisition by
pharmaceutical giant Sanofi-
Aventis tto be a US based target.
According to Giles Somers, senior
healthcare analyst at Datamonitor,
“in terms of prescription
pharmaceutical companies, the
unidentified target could be one of
Biogen Idec, Allergan or Genzyme”.
“To date, the majority of [Sanofi]
acquisitions have taken place in the
generics, consumer healthcare and
vaccine sectors as the company
looks to expand its presence in
areas that both benefit from highgrowth
potential but are also
insulated from the competitive
threat of patent expiration and
generic competition.
“If suggestions of an imminent
$20 billion acquisition are true,
however, this would signal a
notable statement of intent by the
company as it looks to re-shape the
focus of its core prescription
pharmaceuticals business, building
on the major overhaul of the
company’s internal R&D pipeline
last year,” Somers added.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Jul 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Jul 10
